시장보고서
상품코드
1266317

세계의 유전자 검사 시장 : 제공, 검사 종류, 방법, 최종사용자별 - 예측(-2030년)

Genetic Testing Market by Offering, Test Type, Method, End User - Global Forecast to 2030

발행일: | 리서치사: Meticulous Research | 페이지 정보: 영문 177 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 유전자 검사 시장 규모는 2030년까지 282억 4,000만 달러에 달하고, 2023-2030년에 CAGR로 10.4%의 성장이 예측됩니다. 시장 성장은 주로 유전자 검사를 추진하는 정부 대처, 유전성 질환 유행, 질환 조기 발견과 예방에 대한 요구 상승, 종양의 유전자 검사 응용 증가, 시퀀싱 시술 비용 하락에 의해 촉진되고 있습니다.

세계의 유전자 검사 시장에 대해 조사 분석했으며, 시장 규모와 예측, 지역과 부문 분석, 경쟁 상황 등을 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 인사이트

  • 시장 개요
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제

제5장 세계의 유전자 검사 시장 : 제공별

  • 서론
  • 소모품·시약
  • 기구
  • 서비스

제6장 세계의 유전자 검사 시장 : 검사 유형별

  • 서론
  • 산전 검사
  • 예측·발증전 검사
  • 진단 검사
  • 캐리어 검사
  • 신생아 스크리닝
  • 착상전 검사

제7장 세계의 유전자 검사 시장 : 방법별

  • 서론
  • 분자 검사
  • 염색체 검사
  • 생화학 검사

제8장 세계의 유전자 검사 시장 : 최종사용자별

  • 서론
  • 병원·진료소
  • 진단 검사실
  • 기타 최종사용자

제9장 유전자 검사 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 이탈리아
    • 프랑스
    • 영국
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 기타 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제10장 경쟁 상황

  • 서론
  • 주요 성장 전략
  • 경쟁 벤치마킹
  • 시장 점유율 분석(2022년)
    • Illumina, Inc.
    • Laboratory Corporation of America Holdings
    • Thermo Fisher Scientific Inc.
    • Myriad Genetics, Inc.
  • 경쟁 대시보드
    • 업계 리더
    • 시장 차별화 요인
    • 선도 기업
    • 신흥 기업

제11장 기업 개요(사업 개요, 재무 개요, 제품 포트폴리오, 전략적 발전)

  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Perkinelmer Inc.
  • F. Hoffman-La Roche Ltd.
  • Centogene N.V.
  • Konica Minolta, Inc.
  • Opko Health, Inc.
  • Fulgent Genetics, Inc.

제12장 부록

KSM 23.05.08

Genetic Testing Market by Offering (Consumables, Reagents, Instruments, Services), Test Type (Diagnostic, Prenatal, Carrier, Newborn, Preimplantation), Method (Molecular, Chromosomal), End User (Hospitals, Diagnostic Laboratories) - Global Forecast to 2030

The genetic testing market is projected to reach $28.24 billion by 2030, at a CAGR of 10.4% from 2023 to 2030.

Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth of this market is mainly driven by government initiatives promoting genetic testing, the increasing prevalence of genetic disorders, the growing need for the early detection & prevention of diseases, the increasing applications of genetic testing in oncology, and the decreasing costs of sequencing procedures. However, the high cost of genetic testing in low-income countries and its social and ethical implications restrain the growth of the genetic testing market. The growing potential of direct-to-consumer genetic testing and the emerging field of genetic counseling are expected to create growth opportunities for the players operating in this market. However, the low chances of positive, actionable mutations and concerns regarding the security & privacy of genetic data are major challenges to market growth.

Based on offering, in 2023, the consumables & reagents segment is expected to account for the largest share of the market. The key factors contributing to the largest market share of the segment are rising demand for genetic testing, recurring demand for consumables and reagents, and use of consumables & reagents by multiple end users such as hospitals, research laboratories, and diagnostic & testing laboratories. The surge in genetic tests at hospitals and diagnostics labs is one of the key factors for the growing demand for consumables and reagents.

Based on test type, in 2023, the prenatal testing segment is expected to account for the largest share of the market. The key factors contributing to the large market share of this segment are the ability of prenatal tests to detect the genetic risks associated with an infant's health. Also, some invasive prenatal tests are conducted when there is a risk of developing genetic abnormalities in infants, such as a neural tube defect or chromosomal abnormality. These factors are expected to fuel the adoption of prenatal genetic tests.

Based on method, the market is segmented into molecular tests, biochemical tests, and chromosomal tests. In 2023, the molecular tests segment is expected to account for the largest share of the market. Several advantages offered by molecular tests such as high accuracy, fewer false positive results, and short test period, support the large market share of this segment. Additionally, increased government funding for the development of advanced molecular testing, increased research activities, and a rise in test frequencies for genetic disorders are leading to the growing demand for molecular testing.

Based on end user, the hospitals & clinics segment is likely to register the highest CAGR over the forecast period. Growing demand for advanced technology in the genetic screening of hereditary cancers, well-established infrastructure, the increasing use of advanced techniques, and the growing prevalence of chronic diseases are some of the major factors leading to the rapid growth of the hospital & clinics segment.

An in-depth analysis of the geographical scenario of the genetic testing market provides detailed qualitative and quantitative insights into five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region.

In 2023, North America is expected to command the largest share of the genetic testing market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Key factors such as high spending power, the growing importance of early disease diagnosis, government initiatives to increase test frequencies, growing funding for research activities, and high R&D expenditure are responsible for the region's high share of the genetic testing market.

Some of the key players operating in the global genetic testing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), OPKO Health Inc. (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Centogene N.V. (Germany), Konica Minolta, Inc. (Japan), Fulgent Genetics, Inc. (U.S.), and Laboratory Corporation of America Holdings (U.S.).

Scope of the Report:

Genetic Testing Market, by Offering

  • Consumables & Reagents
  • Instruments
  • Services

Genetic Testing Market, by Test Type

  • Diagnostic Testing
  • Predictive and Presymptomatic Testing
  • Newborn Screening
  • Prenatal Testing
  • Preimplantation Testing
  • Carrier Testing

Genetic Testing Market, by Method

  • Molecular Tests
  • Chromosomal Tests
  • Biochemical Tests

Genetic Testing Market, by End User

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others End Users

(Note: Other End Users Include Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, And Contract Research Organizations)

Genetic Testing Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market assessment
    • 2.3.1. Market Size Estimation
      • 2.3.1.1. Bottom-up Approach
      • 2.3.1.2. Top-down Approach
      • 2.3.1.3. Growth Forecast
  • 2.4. Assumptions for the study
  • 2.5. Limitations for the study

3. Executive Summary

4. Market Insights

  • 4.1. Market Overview
  • 4.2. Drivers
    • 4.2.1. Government Initiatives Promoting Genetic Testing
    • 4.2.2. Increasing Prevalence of Genetic Disorders
      • 4.2.2.1. Sickle Cell Disease
      • 4.2.2.2. Cystic Fibrosis
      • 4.2.2.3. Down Syndrome and Neural Tube Defects
      • 4.2.2.4. Parkinson's Disease and Alzheimer's Disease
      • 4.2.2.5. Diabetes
    • 4.2.3. Growing Need for the Early Detection & Prevention of Diseases
    • 4.2.4. Increasing Applications of Genetic Testing in Oncology
    • 4.2.5. Decreasing Costs of Sequencing Procedures
  • 4.3. Restraints
    • 4.3.1. High Cost of Genetic Testing in Low-Income Countries
    • 4.3.2. Social and Ethical Implications of Genetic Testing
  • 4.4. Opportunities
    • 4.4.1. Growing Potential of Direct-To-Consumer Genetic Testing
    • 4.4.2. Emerging Field of Genetic Counseling
  • 4.5. Challenges
    • 4.5.1. Low Chances of Positive, Actionable Mutations
    • 4.5.2. Concerns Regarding the Security & Privacy of Genetic Data

5. Global Genetic Testing Market, by Offering

  • 5.1. Introduction
  • 5.2. Consumables & Reagents
  • 5.3. Instruments
  • 5.4. Services

6. Global Genetic Testing Market, by Test Type

  • 6.1. Introduction
  • 6.2. Prenatal Testing
  • 6.3. Predictive and Presymptomatic Testing
  • 6.4. Diagnostic Testing
  • 6.5. Carrier Testing
  • 6.6. Newborn Screening
  • 6.7. Preimplantation Testing

7. Global Genetic Testing Market, by Method

  • 7.1. Introduction
  • 7.2. Molecular Tests
  • 7.3. Chromosomal Tests
  • 7.4. Biochemical Tests

8. Global Genetic Testing Market, by End User

  • 8.1. Introduction
  • 8.2. Hospitals and Clinics
  • 8.3. Diagnostic Laboratories
  • 8.4. Other End Users

9. Genetic Testing Market, by Geography

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. Italy
    • 9.3.3. France
    • 9.3.4. U.K.
    • 9.3.5. Spain
    • 9.3.6. Rest of Europe (RoE)
  • 9.4. Asia-pacific
    • 9.4.1. Japan
    • 9.4.2. China
    • 9.4.3. India
    • 9.4.4. Rest of Asia-Pacific (RoAPAC)
  • 9.5. Latin America
  • 9.6. Middle East & Africa

10. Competitive Landscape

  • 10.1. Introduction
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Market Share Analysis (2022)
    • 10.4.1. Illumina, Inc.
    • 10.4.2. Laboratory Corporation of America Holdings
    • 10.4.3. Thermo Fisher Scientific Inc.
    • 10.4.4. Myriad Genetics, Inc.
  • 10.5. Competitive Dashboard
    • 10.5.1. Industry Leaders
    • 10.5.2. Market Differentiators
    • 10.5.3. Vanguards
    • 10.5.4. Emerging Companies

11. Company profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)

  • 11.1. Thermo Fisher Scientific Inc.
  • 11.2. Illumina, Inc.
  • 11.3. Laboratory Corporation of America Holdings
  • 11.4. Myriad Genetics, Inc.
  • 11.5. Natera, Inc.
  • 11.6. Perkinelmer Inc.
  • 11.7. F. Hoffman-La Roche Ltd.
  • 11.8. Centogene N.V.
  • 11.9. Konica Minolta, Inc.
  • 11.10. Opko Health, Inc.
  • 11.11. Fulgent Genetics, Inc.

12. Appendix

  • 12.1. Available Customization
  • 12.2. Related Reports
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제